Want to join the conversation?
$BIIB said Bioverativ will continue commercialization of ELOCTATE and ALPROLIX, indicated for treatment of hemophilia A and B under $BIIB's existing collaboration agreement with Swedish Orphan Biovitrum AB. After spin-off, Bioverativ expects to continue development of ELOCTATE and ALPROLIX. Bioverativ plans to trade under "BIVV" ticker.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.